All data are based on the daily closing price as of December 6, 2024
h
Hugel
145020.KQ
186.69 USD
-3.96
-2.08%
Overview
Last close
186.69 usd
Market cap
2.06B usd
52 week high
230.24 usd
52 week low
78.09 usd
Target price
254.09 usd
Valuation
P/E
N/A
Forward P/E
18.5529
Price/Sales
8.2397
Price/Book Value
3.6391
Enterprise Value
1.79B usd
EV/Revenue
6.9926
EV/EBITDA
14.7851
Key financials
Revenue TTM
241.99M usd
Gross Profit TTM
173.42M usd
EBITDA TTM
107.54M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
899.41B usd
Net debt
N/A usd
About
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.